ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
  • Abstract Number: 1114
    Pachymeningitis: The Mayo Clinic Experience
  • Abstract Number: 1236
    Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials
  • Abstract Number: 0743
    Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
  • Abstract Number: 0379
    Pain Sensitivity in Axial Spondyloarthritis – Comparisons Between Patients and Controls, Women and Men, and Between Different Pain Groups
  • Abstract Number: 0718
    Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
  • Abstract Number: 1192
    Palliative Care for the Rheumatologist: An Educational and Patient Care Intervention
  • Abstract Number: 1613
    Pandemic and Patients: Examining Health-Related Behaviors of Patients with Systemic Sclerosis During the COVID-19 Pandemic
  • Abstract Number: 1719
    Pandemic-Associated Complications in Pregnant Women with Rheumatic Diseases
  • Abstract Number: 1265
    Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
  • Abstract Number: 1649
    Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder
  • Abstract Number: 1373
    Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis
  • Abstract Number: 1792
    Participation in Psoriatic Arthritis (PART2) – a Cross-sectional Study of Work Impairment in Psoriatic Arthritis Patients in the Netherlands
  • Abstract Number: 1104
    Pathogenic UBA1 Variants in Japanese Patients with Relapsing Polychondritis
  • Abstract Number: 0555
    Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data
  • Abstract Number: 1634
    Patient Activation and Health Literacy in the Pediatric to Adult Transition in Juvenile Systemic Lupus Erythematosus: Patient and Health Care Team Perspectives
  • Abstract Number: 0254
    Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
  • Abstract Number: 0317
    Patient and Physician Perspectives on EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): A Qualitative Interview Study
  • Abstract Number: 0629
    Patient and Physician Satisfaction with Telemedicine Utilization for Delivery of Care in Patients with SLE – A Single Centre Experience
  • Abstract Number: 1814
    Patient Characteristics and Clinical Features Associate with Health-Related Quality of Life in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
  • Abstract Number: 0814
    Patient Characteristics, Efficacy, and Treatment Patterns of Tofacitinib Monotherapy in Patients with RA: Contextualization of Randomized Controlled Trial Results with Real-world Data
  • Abstract Number: 1924
    Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utilization and Mortality in Rheumatoid Arthritis Within Independent Real-World Datasets
  • Abstract Number: 0359
    Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)
  • Abstract Number: 1913
    Patient Perceptions of Telemedicine Use in Rheumatology Clinics During the COVID-19 Pandemic: An Analysis from the COVID-19 Global Rheumatology Alliance
  • Abstract Number: 1157
    Patient Perspective on the Non Medical Switch of Originator to Its Biosimilar in Inflammatory Arthritis Using a Social Media Survey
  • Abstract Number: 0668
    Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence
  • Abstract Number: 1277
    Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms
  • Abstract Number: 1161
    Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
  • Abstract Number: 1169
    Patient Preferences for Outcome Measures for a Pragmatic Knee Osteoarthritis (OA) Clinical Trial: Results of a Cross-Sectional Patient Survey That Included Racial/Ethnic Minorities
  • Abstract Number: 1418
    Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Abstract Number: 1122
    Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities
  • Abstract Number: 0753
    Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of Adalimumab and Etanercept in Patients with Inflammatory Rheumatic Diseases
  • Abstract Number: 1624
    Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA
  • Abstract Number: 0745
    Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
  • Abstract Number: 1911
    Patient’s and Rheumatologist’s Perspectives on the Burden of Adverse Drug Reactions Attributed to Biologics: A Qualitative Study
  • Abstract Number: 1289
    Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
  • Abstract Number: 0098
    Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
  • Abstract Number: 0103
    Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
  • Abstract Number: 0764
    Patients with Juvenile Systemic Sclerosis Have a Distinct Pattern of Organ Involvement: Results from the Juvenile Systemic Sclerosis Inception Cohort
  • Abstract Number: 0710
    Patients with Recent Onset, Active Polymyositis (PM), Dermatomyositis (DM) and Antisynthetase Syndrome (ASS) Have Reduced Muscle Endurance but Not Reduced Muscle Strength Compared to Patients with Established, Low-active Disease
  • Abstract Number: 1163
    Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence
  • Abstract Number: 0263
    Patterns of Medication Switching in Juvenile Idiopathic Arthritis: A Retrospective Analysis of a National Administrative Claims Database
  • Abstract Number: 0772
    Pediatric Craniofacial Scleroderma: Assessing Handheld 3D Stereophotogrammetric Imaging Feasibility and Reliability
  • Abstract Number: 1620
    Pediatric Onset (< 16 Years) Non-infectious Uveitis: Results from Spanish National Registry
  • Abstract Number: 1636
    Pediatric Rheumatologists’ Perspectives on Diagnosis, Treatment and Outcomes of Sjögren Syndrome in Children and Adolescents
  • Abstract Number: 0512
    Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
  • Abstract Number: 0665
    Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
  • Abstract Number: 1593
    Perceived Impact of the COVID-19 Pandemic on Physical Activity Among Adult Patients with Rheumatologic Disease
  • Abstract Number: 1604
    Perceptions About COVID-19 Vaccination Among Patients with Rheumatic Diseases Enrolled in a National Patient Registry
  • Abstract Number: 1843
    Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
  • Abstract Number: 0398
    Performance of ACR CRISS Score and Revised ACR CRISS Response in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc) in Which Background Immunosuppressive Therapies (bIST) Were Allowed
  • Abstract Number: 0702
    Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
  • Abstract Number: 0748
    Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia
  • Abstract Number: 0349
    Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
  • Abstract Number: 0320
    Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
  • Abstract Number: 0335
    Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
  • Abstract Number: 0404
    Perifollicular Hypopigmentation in Systemic Sclerosis: Associations with Clinical Features and Internal Organ Involvement
  • Abstract Number: 1197
    Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation
  • Abstract Number: 1842
    Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
  • Abstract Number: 0056
    Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Patients with Healthy Controls
  • Abstract Number: 0841
    Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry
  • Abstract Number: 0810
    Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
  • Abstract Number: 1213
    Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge
  • Abstract Number: 1064
    Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Private Rheumatology Practice: Patient Outcomes
  • Abstract Number: 0823
    Pharmacokinetic and Pharmacodynamic Evaluation of a Proposed Biosimilar MSB11456 versus Both the US-licensed and EU-approved Tocilizumab: Results of a Randomized, Double-blind, Parallel-group, Single-dose Trial in Healthy Adults
  • Abstract Number: 1700
    Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
  • Abstract Number: 1567
    Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients
  • Abstract Number: 0411
    Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial
  • Abstract Number: 1441
    Pharmacological Characterization of GLPG3667, a Selective TYK2 Inhibitor for Treatment of Inflammatory Diseases
  • Abstract Number: 1509
    Pharmacological Inhibition of MALT1 Reverses Activation-Induced Metabolic Reprogramming and Ameliorates Autoimmune Pathogenesis in Multiple Animal Models of Chronic Inflammation
  • Abstract Number: 0416
    Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis
  • Abstract Number: 1829
    Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
  • Abstract Number: 0185
    Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
  • Abstract Number: L05
    Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
  • Abstract Number: 0184
    Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP
  • Abstract Number: 1579
    Phenome-Wide Association of Gout Risk Loci
  • Abstract Number: 1106
    Phenotypes and Genotypes of NLRP3-AID in Chinese Adult Patients
  • Abstract Number: 1665
    Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
  • Abstract Number: 1033
    Physical Inactivity Among Adults with Specific Chronic Conditions, by Arthritis Status, 49 States and District of Columbia, Behavioral Risk Factor Surveillance System, 2019
  • Abstract Number: 1233
    Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
  • Abstract Number: 0824
    Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting
  • Abstract Number: 1182
    Pilot Health Literacy Curriculum Addressing Skills and Content Knowledge for Adult and Pediatric Rheumatology Fellows
  • Abstract Number: 1209
    Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors
  • Abstract Number: 1247
    Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis
  • Abstract Number: 0461
    Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
  • Abstract Number: 1498
    Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus
  • Abstract Number: 1172
    Podcast-Based Learning, a Valuable Tool for Learning Rheumatology
  • Abstract Number: 1653
    Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis
  • Abstract Number: 0618
    Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases
  • Abstract Number: 0419
    Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
  • Abstract Number: 1943
    Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
  • Abstract Number: 0777
    Potential Biomarkers of Cognitive Impairment in the Context of Childhood-Onset Systemic Lupus Erythematosus
  • Abstract Number: 1547
    Potential Predictors of Outcome for Anakinra Treatment in COVID-19 Patients with Macrophage Activation Syndrome
  • Abstract Number: 1522
    Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
  • Abstract Number: 1559
    Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India
  • Abstract Number: 0768
    Poverty and Length of Stay in Children Hospitalized with Pediatric Systemic Lupus Erythematosus: An Analysis of the 2016 Kids’ Inpatient Database
  • Abstract Number: 1745
    Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis
  • Abstract Number: 1015
    Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis
  • Abstract Number: 0518
    Predicted Expression of Genes Involved in the Thiopurine Metabolic Pathway Is Associated with Azathioprine Discontinuation Due to Bone Marrow Toxicity
  • Abstract Number: 1729
    Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
  • Abstract Number: 1268
    Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
  • Abstract Number: 1200
    Predicting Progression to RA in Patients with Seropositive Arthralgia
  • Abstract Number: 1228
    Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting
  • Abstract Number: 0076
    Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
  • Abstract Number: 0579
    Predicting Treatment Change in Rheumatoid Arthritis Patients Treated with TNF Inhibitors as First-Line Biologic Agent
  • Abstract Number: 1212
    Prediction of 1-Year Intravenous Abatacept Retention in Patients with RA Using Novel Machine Learning Techniques: Directionality and Importance of Predictors
  • Abstract Number: 1383
    Prediction of Digital Ulcers in Patients with Systemic Sclerosis Based on the Use of Platelet Inhibitors and Other Parameters – A EUSTAR Study on Derivation and Validation of a Clinical Prediction Model
  • Abstract Number: 1789
    Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles
  • Abstract Number: 0388
    Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
  • Abstract Number: 1631
    Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis
  • Abstract Number: 1314
    Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis
  • Abstract Number: 1348
    Predictors for Achievement of Low Disease Activity at Week 56 in Patients with Psoriatic Arthritis Who Received Upadacitinib 15 Mg Once Daily: Pooled Analysis of Two Phase 3 Studies
  • Abstract Number: 0387
    Predictors for Progressive Fibrosis in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases
  • Abstract Number: 0926
    Predictors of 1-Year Treatment Response Among Upadacitinib-Treated Patients with Ankylosing Spondylitis: A Post Hoc Analysis
  • Abstract Number: 1294
    Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and MASTERPLANS Consortium
  • Abstract Number: 1205
    Predictors of Discordance Between Patient and Physician Global Assessment in Patients with Rheumatoid Arthritis
  • Abstract Number: 1143
    Predictors of Engagement in Bone Health Care Among Rural Veterans at Risk for Osteoporosis
  • Abstract Number: 0585
    Predictors of Health-Related Quality of Life in Rheumatoid Arthritis Patients
  • Abstract Number: 0413
    Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort
  • Abstract Number: 0779
    Predictors of Mortality in a Series of 1528 Brazilian Childhood-onset Systemic Lupus Erythematosus Patients
  • Abstract Number: 0683
    Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis
  • Abstract Number: 1410
    Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis
  • Abstract Number: 1276
    Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
  • Abstract Number: 1831
    Predictors of Response, Adverse Events and Treatment Retention in Psoriatic Arthritis Patients Treated with Golimumab in a Prospective, Observational Registry
  • Abstract Number: 1237
    Predictors of Response: Baseline Characteristics and Early Treatment Responses Associated with Achievement of Remission and Low Disease Activity Among Upadacitinib-Treated Patients with Rheumatoid Arthritis
  • Abstract Number: 0439
    Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
  • Abstract Number: 0838
    Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
  • Abstract Number: 1155
    Pregnancy Experiences and Unmet Needs for Women of Childbearing Age with Chronic Rheumatic Disease in China
  • Abstract Number: 0070
    Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
  • Abstract Number: 0499
    Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires
  • Abstract Number: 1541
    Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19
  • Abstract Number: 1614
    Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain
  • Abstract Number: 1378
    Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
  • Abstract Number: 1841
    Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
  • Abstract Number: 0574
    Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
  • Abstract Number: 1785
    Prevalence and Incidence of PsA in Germany – a Cohort Study with 65 Million Participants
  • Abstract Number: 0290
    Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
  • Abstract Number: 0642
    Prevalence and Risk Factors for Cardio-metabolic Abnormalities in Patients with Inflammatory Arthritis Attending Cardio-rheumatology Primary Prevention Clinics
  • Abstract Number: 0862
    Prevalence and Risk Factors for Herpes Zoster Reactivation in 1542 Patients with Rheumatic Diseases
  • Abstract Number: 1148
    Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases
  • Abstract Number: 0843
    Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States
  • Abstract Number: 1145
    Prevalence of and Risk Factors for Vertebral Fractures and Low Bone Mass Density Among Women Aging with HIV in Peru
  • Abstract Number: 1517
    Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
  • Abstract Number: 0126
    Prevalence of Dyslipidemia in Fibromyalgia: A Single Center Case Control Study from South India
  • Abstract Number: 1043
    Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study
  • Abstract Number: 1561
    Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic
  • Abstract Number: 0225
    Prevalence of Sexual Dysfunction and Depression in German Patients with Psoriasis and Psoriatic Arthritis – Results of the PIPPA Study
  • Abstract Number: 0332
    Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
  • Abstract Number: 0412
    Prevalence, Distribution, Clinical Correlates and Outcomes of Upper Extremity Macrovascular Disease in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
  • Abstract Number: 0064
    Prevalence, Incidence and Predictor Features of Uveitis in Spondyloarthritis in a Canadian Cohort
  • Abstract Number: 0734
    Primary Total Knee Arthroplasty for Knee Osteoarthritis Among Younger versus Older Individuals: Cross-sectional Study of Surgical Appropriateness and Surgeon Decision-Making
  • Abstract Number: 0677
    Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
  • Abstract Number: 0666
    Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
  • Abstract Number: 0312
    Prognostic Value of Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome
  • Abstract Number: 1515
    Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T Cells Are Expanded in Early Rheumatoid Arthritis and Correlate with Response to Treatment
  • Abstract Number: 0314
    PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome
  • Abstract Number: 1892
    Promotion of Autoimmune Arthritis via Tryptophan Metabolism and Production of the Bacterial-Derived Tryptophan Metabolite Indole
  • Abstract Number: 0248
    Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
  • Abstract Number: 0434
    Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis
  • Abstract Number: 0961
    Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
  • Abstract Number: 1010
    Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease
  • Abstract Number: 0631
    Provider Assessment of Telehealth Utility During COVID-19
  • Abstract Number: 1715
    Providing High Quality Family Care Planning for Women with Rheumatic Disease in Rheumatology Clinics: Perspectives of Rheumatology Clinicians
  • Abstract Number: 1791
    Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry
  • Abstract Number: 0241
    Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
  • Abstract Number: 1355
    Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study
  • Abstract Number: 0046
    Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
  • Abstract Number: 1827
    Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort
  • Abstract Number: 0846
    Psychometric Evaluation and Measurement Invariance of English and French Versions of the UCLA Loneliness Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
  • Abstract Number: 0267
    Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort
  • Abstract Number: 0797
    Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis
  • Abstract Number: 1100
    Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: A Case Series of 13 Patients
  • Abstract Number: 0276
    Pulse Pressure as a Predictor of Carotid Plaque in Rheumatoid Arthritis Patients
  • Abstract Number: 1503
    Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology